Altimmune, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Altimmune, Inc. on June 25, 2024, with the earliest event reported on that same date. The filing addresses significant changes in executive leadership and regulatory disclosures.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance data.
Material Changes
- Executive Departure: Richard Eisenstadt, the Company's Chief Financial Officer, passed away unexpectedly.
- Executive Appointment: Andrew Shutterly was appointed as acting Chief Financial Officer, principal financial officer, and principal accounting officer, effective immediately following Mr. Eisenstadt's death.
- Background: Mr. Shutterly, age 36, has served as Corporate Controller since February 2023 and joined the Company in October 2020 as Assistant Controller.
Guidance, Outlook, and Risks
The filing references a press release issued on June 26, 2024 (Exhibit 99.1), which is incorporated by reference but not detailed in the text provided. No specific financial guidance, outlook, or new risk factors are explicitly stated in the body of this 8-K. The Company noted it will enter into a standard indemnification agreement with Mr. Shutterly.
Investor Verification Checklist
- Verify the full text of the June 26, 2024 press release (Exhibit 99.1) for additional context on the leadership transition.
- Confirm the timeline for a permanent Chief Financial Officer search, as Mr. Shutterly is currently in an acting capacity.
- Review the Company's most recent Form 10-K or 10-Q for the latest financial position, as this 8-K contains no financial data.